Skip to Main Content
Contribute Try STAT+ Today

The escalating cost of the only HIV prevention pill may have been a key factor hindering widespread use in recent years, according to a new analysis by U.S. government researchers, underscoring long-standing concerns over the ability to eradicate the virus.

From 2014 to 2018, total payments made by government programs, commercial insurers, and patients for Truvada, which was approved to prevent HIV in 2012, jumped from $114 million to nearly $2.1 billion. Yet the number of people who were given prescriptions in 2018 was just 204,700, which amounted to less than 20% of those estimated who could have benefited from the medication.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Pursuant to Trump’s EO on drug importation, people with HIV could apply for waivers, subject to Section 804J2, to import it for personal use. There’s nothing in the law that prevents a waiver to allow imports of generic Truvada approved in other countries. Food for thought for those who follow this closely. The generic is about $800 for three months in Canada, compared to the brand, $1700/month here. itabine%252ftenofovir/

Comments are closed.